الفهرس 
AknowledgementOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
This study was prospectively performed within one year at Clinical Hematology Unit of Internal Medicine Department in Assiut University Hospital and included 30 patients (newly and previously) diagnosed with myeloproliferative neoplasms. All the patients that fulfill myeloproliferative neoplasms diagnostic criteria were included in the study while markedly obese patients were excluded and also those who refused to do echocardiography. The study included (43.3%) cases as CML, (26.6%) cases as PV, (6.6%) cases as ET and (23.3%) cases as PMF. In addition another 30 patients with other hematological diseases (diseased control group) and 30 healthy subjects (healthy control group) were also, included All the patients included in this study and control groups subjected to the following Careful history taking and through clinical examination Investigations in the form of : Complete blood count (CBC) , Janus kinase 2 (JAK 2) mutation analysis , Philadelphia chromosome detection and bone marrow studies. Renal and liver function tests were also done Chest x ray to detect pulmonary diseases or congenital cardiac abnormalities and Abdominal ultrasound for hepato-splenomegaly and renal abnormalitiesTransthoracic echocardiography was done for patients of the study and two control groups to detect morphological and functional cardiac changes Transthoracic echocardiography including Left Ventricle assessment and right Ventricle assessment Atrial assessment of size.Cardiac valves: Morphology, presence and severity of stenosis or regurgitation.Pericardium: Presence and size of pericardial effusion, assessment of hemodynamic effects of pericardial effusion (if present) and Presence of intracardiac masses or thrombi.